5-甲氧基-1H-吲哚-2-羧酸 | 21778-81-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-甲氧基-1H-吲哚-2-羧酸
• 中文别名: 5-甲氧基-1H-吲哚-2-甲醛
• 英文名称: 5-methoxy-1H-indole-2-carbaldehyde
• 英文别名: 5-methoxyindole-2-carboxaldehyde
• CAS: 21778-81-4
• 化学式: C₁₀H₉NO₂
• mdl: MFCD00297147
• 分子量: 175.187
• InChiKey: IEHXXJMABHGXCG-UHFFFAOYSA-N

物化性质

• 熔点：
  140-141 °C
• 沸点：
  375.2±22.0 °C(Predicted)
• 密度：
  1.273±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319
• 储存条件：
  存储条件：2-8°C，宜采用惰性气体保护。

反应信息

• 作为反应物：
  描述：

  5-甲氧基-1H-吲哚-2-羧酸 在 manganese(IV) oxide 作用下， 以 四氢呋喃 、 乙醚 、 氯仿 为溶剂， 反应 1.5h， 生成 (5-甲氧基-1H-吲哚-2-基)苯基甲酮
  参考文献：
  名称：

  4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione Inhibitors of the Checkpoint Kinase Wee1. Structure−Activity Relationships for Chromophore Modification and Phenyl Ring Substitution

  摘要：

  High-throughput screening has identified a novel class of inhibitors of the checkpoint kinase Wee1, which have potential for use in cancer chemotherapy. These inhibitors are based on a 4-phenylpyrrolo[3,4-c]carbazole- 1,3(2H,6H)-dione template and have been shown by X-ray crystallography to bind at the ATP site of the enzyme. An extensive study of the effects of substitution around this template has been carried out, which has identified substituents which lead to improvements in potency and selectivity for Wee1. While retention of the maleimide ring and pendant 4-phenyl group is necessary for potency, replacement of the carbazole nitrogen by oxygen is well tolerated and results in improved Wee1 selectivity against the related checkpoint kinase Chk1. Wee1 potency and selectivity are also enhanced by the incorporation of lipophilic functionality at the 2'-position of the 4-phenyl ring, and Wee1 selectivity against Chk1 is favored by C3-C5 alkyl substitution of the carbazole nitrogen. These studies provide a basis for the design of active analogues of the pyrrolocarbazole lead with improved physical properties.

  DOI：

  10.1021/jm0512591
• 作为产物：
  描述：

  3-氯-4-甲氧基苯胺 在 盐酸 、 sodium amide 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 丙酮 、 苯 为溶剂， 反应 49.0h， 生成 5-甲氧基-1H-吲哚-2-羧酸
  参考文献：
  名称：

  Efficient selective synthesis of 2-substituted indoles from complex-base-promoted arynic cyclisations

  摘要：

  在络合碱 NaNH2-ButONa 的存在下，通过对甲基酮的卤代芳基亚胺进行选择性芳基环化，以及通过 PhCH2SH-AlCl3 开启四氢硫代吡喃吲哚（也是从亚胺的芳基环化中获得），可以有效地获得 2-取代的吲哚。

  DOI：

  10.1039/a702548c

文献信息

• FIBROSIS INHIBITOR
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1479384A1

  公开（公告）日：2004-11-24

  Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2): (1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

  药物作为器官或组织的纤维化抑制剂而有用，包括具有以下式（I）的化合物： 其中环Z是可选择取代的吡咯环等；W2是-CO-，-SO2-，可选择取代的C1-C4烷基等；Ar2是可选择取代的芳基等；W1和Ar1表示如下（1）和（2）： （1）W1是可选择取代的C1-C4烷基等；Ar1是可选择取代的具有1至4个氮原子作为环形成原子的双环杂芳基： （2）W1是可选择取代的C2-C5烷基，可选择取代的C2-C5烯基等；以及 Ar1是芳基或单环杂芳基，其在相对于W1的结合位置的邻位或间位处被羧基，烷氧羰基等取代， 或其药学上可接受的盐。
• [EN] 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS<br/>[FR] DERIVES DE PIPERIDINE 1,4 DISUBSTITUEE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BETAHSD1
  申请人：ASTRAZENECA AB

  公开号：WO2004033427A1

  公开（公告）日：2004-04-22

  The use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of 11βHSD1 is described.

  使用式(I)的化合物制造用于抑制11βHSD1的药物。
• Carbene‐Catalyzed Enantioselective Aromatic N‐Nucleophilic Addition of Heteroarenes to Ketones
  作者：Yonggui Liu、Guoyong Luo、Xing Yang、Shichun Jiang、Wei Xue、Yonggui Robin Chi、Zhichao Jin

  DOI：10.1002/anie.201912160

  日期：2020.1.2

  and optical purities. Our reaction involves the formation of an unprecedented aza-fulvene-type acylazolium intermediate. A broad range of N-heteroaromatic aldehydes and electron-deficient ketone substrates works effectively in this transformation. Several of the chiral N,O-acetal products afforded through this protocol exhibit excellent antibacterial activities against Ralstonia solanacearum (Rs) and

  杂芳基醛的芳族氮原子被卡宾催化剂活化以与酮亲电子试剂反应。以良好至优异的产率和光学纯度提供多功能的环状N，O-乙缩醛产物。我们的反应涉及空前的氮杂富烯型酰基唑鎓中间体的形成。各种各样的N-杂芳族醛和缺电子的酮底物可以有效地实现这种转化。通过该协议提供的几种手性N，O-乙缩醛产品表现出优异的抗青枯菌（Rsstonia solanacearum）的抗菌活性，在开发用于植物保护的新型农业化学品中具有重要的价值。
• Pyrrole derivatives
  申请人：——

  公开号：US20030181496A1

  公开（公告）日：2003-09-25

  Pyrrole derivatives represented by the following formula: 1 wherein Ring Z is an optionally substituted pyrrole ring, etc.; W 2 is —CO—, —SO 2 —, an optionally substituted C 1 -C 4 alkylene, etc.; Ar 2 is an optionally substituted aryl, etc.; W 2 and Ar 1 mean the following (1) and (2): (1) W 1 is an optionally substituted C 1 -C 4 alkylene, etc.; Ar 1 is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W 1 is an optionally substituted C 2 -C 5 alkylene, an optionally substituted C 2 -C 5 alkenylene, etc.; and Ar 1 is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W 1 , or a pharmaceutically acceptable salt thereof These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.

  以下是用中文翻译的结果： 由以下公式表示的吡咯衍生物： 其中环Z是可选择取代的吡咯环等；W 2 是—CO—，—SO 2 —，可选择取代的C 1 -C 4 烷基等；Ar 2 是可选择取代的芳基等；W 2 和Ar 1 表示如下（1）和（2）： （1）W 1 是可选择取代的C 1 -C 4 烷基等；Ar 1 是具有1至4个氮原子作为环形成原子的可选择取代的双环杂芳基： （2）W 1 是可选择取代的C 2 -C 5 烷基，可选择取代的C 2 -C 5 烯基等；Ar 1 是芳基或单环杂芳基，其在与W 1 的结合位置相对应的邻位或间位处被羧基，烷氧羰基等取代， 或其药学上可接受的盐 这些化合物可用作器官或组织的纤维化抑制剂等药物。
• [EN] HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PAD
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019058393A1

  公开（公告）日：2019-03-28

  Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.

  公式（I）、（II）和（III）的杂环化合物以及它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物在此处描述。本文描述的化合物及其多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物是PAD4抑制剂，可能在治疗各种疾病中有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、多发性硬化和牛皮癣。